Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of two nucleoside combination alternatives in virologically suppressed HIV-1 patients on lamivudine
2005-000005-65Phase 3Active
- Sponsor
- Infectious Diseases Department, Hospital Clínic de Barcelona
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abacavir + lamivudine, tenofovir disoproxil fumarate, emtricitabine and lamivudine in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Infectious Diseases Department, Hospital Clínic de Barcelona. Started May 2006; status: active.
02
Drugs
abacavir + lamivudinetenofovir disoproxil fumarateemtricitabinelamivudine
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-000005-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000005-65.